287 related articles for article (PubMed ID: 19153090)
21. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome.
Rabinson J; Meltcer S; Zohav E; Gemer O; Anteby EY; Orvieto R
Fertil Steril; 2008 Feb; 89(2):472-4. PubMed ID: 17582402
[TBL] [Abstract][Full Text] [Related]
22. Effect of coasting on cycle outcome during in vitro fertilization/intracytoplasmic sperm injection cycles in hyper-responders.
Kovács P; Mátyás S; Kaali SG
Fertil Steril; 2006 Apr; 85(4):913-7. PubMed ID: 16580374
[TBL] [Abstract][Full Text] [Related]
23. GnRH antagonists.
Coccia ME; Comparetto C; Bracco GL; Scarselli G
Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S44-56. PubMed ID: 15196716
[TBL] [Abstract][Full Text] [Related]
24. [Alternative approaches to ovarian stimulation].
Alvarez S
Gynecol Obstet Fertil; 2007 Sep; 35(9):885-9. PubMed ID: 17825596
[TBL] [Abstract][Full Text] [Related]
25. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
Yates AP; Rustamov O; Roberts SA; Lim HY; Pemberton PW; Smith A; Nardo LG
Hum Reprod; 2011 Sep; 26(9):2353-62. PubMed ID: 21672928
[TBL] [Abstract][Full Text] [Related]
26. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?
Orvieto R; Meltzer S; Rabinson J; Gemer O; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1297-300. PubMed ID: 18249369
[TBL] [Abstract][Full Text] [Related]
27. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited.
Zarek SM; Muasher SJ
Fertil Steril; 2011 Jun; 95(8):2449-55. PubMed ID: 21550037
[TBL] [Abstract][Full Text] [Related]
28. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
[TBL] [Abstract][Full Text] [Related]
29. GnRH antagonist in in vitro fertilization: where we are now.
Shapiro DB; Mitchell-Leef D
Minerva Ginecol; 2003 Oct; 55(5):373-88. PubMed ID: 14581880
[TBL] [Abstract][Full Text] [Related]
30. Role of gonadotropin-releasing hormone antagonists in poor responders.
Mahutte NG; Arici A
Fertil Steril; 2007 Feb; 87(2):241-9. PubMed ID: 17113088
[TBL] [Abstract][Full Text] [Related]
31. The use of lead follicle diameter to initiate gonadotropin-releasing hormone antagonist does not affect in vitro fertilization clinical pregnancy, implantation, or live birth rates: a prospective, randomized study.
Dayal MB; Frankfurter D; O'Hern C; Peak D; Dubey A; Gindoff PR
Fertil Steril; 2009 Dec; 92(6):2047-9. PubMed ID: 19591990
[TBL] [Abstract][Full Text] [Related]
32. [Natural cycle in vitro fertilization cycle in poor responders].
Reyftmann L; Déchaud H; Loup V; Anahory T; Brunet-Joyeux C; Lacroix N; Hamamah S; Hédon B
Gynecol Obstet Fertil; 2007 Apr; 35(4):352-8. PubMed ID: 17336129
[TBL] [Abstract][Full Text] [Related]
33. Are GnRH antagonists comparable to agonists for use in IVF?
Huirne JA; Homburg R; Lambalk CB
Hum Reprod; 2007 Nov; 22(11):2805-13. PubMed ID: 17872909
[TBL] [Abstract][Full Text] [Related]
34. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
[TBL] [Abstract][Full Text] [Related]
35. Optimal stimulation protocols for in vitro fertilization.
Muasher SJ; Abdallah RT; Hubayter ZR
Fertil Steril; 2006 Aug; 86(2):267-73. PubMed ID: 16753157
[TBL] [Abstract][Full Text] [Related]
36. Comparison of different treatment strategies in IVF with cumulative live birth over a given period of time as the primary end-point: methodological considerations on a randomized controlled non-inferiority trial.
Eijkemans MJ; Heijnen EM; de Klerk C; Habbema JD; Fauser BC
Hum Reprod; 2006 Feb; 21(2):344-51. PubMed ID: 16239317
[TBL] [Abstract][Full Text] [Related]
37. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry.
Griesinger G; Felberbaum R; Diedrich K
Hum Reprod; 2005 Sep; 20(9):2373-5. PubMed ID: 15932915
[TBL] [Abstract][Full Text] [Related]
38. Comparison between "short" and "long" protocols in an ICSI programme.
Loutradis D; Stefanidis K; Drakakis P; El Sheikh A; Milingos S; Antsaklis A; Michalas S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):69-72. PubMed ID: 15866089
[TBL] [Abstract][Full Text] [Related]
39. Ovarian hyperstimulation syndrome prevention strategies: oral contraceptive pills-dual gonadotropin-releasing hormone agonist suppression with step-down gonadotropin protocols.
Damario MA
Semin Reprod Med; 2010 Nov; 28(6):468-74. PubMed ID: 21082505
[TBL] [Abstract][Full Text] [Related]
40. GnRH agonist long protocol vs. a single 3-mg gnRH antagonist: a comparison of 2 protocols for pituitary down-regulation in oocyte donor-controlled ovarian hyperstimulation cycles.
Erb TM; Wakim AN
J Reprod Med; 2008 May; 53(5):331-7. PubMed ID: 18567278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
